When Emerging Biopharma (EBP) companies consider globalization, what criteria guide their choice of markets to enter? In Japan, the evaluation of innovative new drugs has advanced significantly, creating an environment that is more open and attractive for startups and EBPs than ever before. Support from AMED, PMDA, and other government organizations has expanded, fostering new business opportunities through reforms in pharmaceutical regulations and drug pricing, improvements in clinical trial infrastructure, and increased opportunities for talent exchange and business matching. Japan now stands as a strategic gateway to Asia, especially for US and European startups. This session will share the latest updates and insights from Japan for entrepreneurs exploring opportunities in the Asian region.